A recently published report by Mordor Intelligence analyzes future projections, growth drivers and the key trends that are shaping the rapidly growing market for cancer immunotherapy. The report puts the valuation of this market in 2025 at $144.8 billion and projects that it will expand to $311.4 billion by 2031.
This expected expansion shows the extent to which patients and clinicians are increasingly accepting immunotherapy as a major approach in cancer care. As a result, these treatments are shifting from being niche therapies and are becoming recognized treatment options by the mainstream medical community and the patients they serve.
The rise in cancer immunotherapy acceptance has been helped by regulatory approvals granted in different jurisdictions, and these advanced therapies, such as targeted immune system treatments, oncolytic virus therapies, and cell-based interventions, are garnering widespread appeal.
The report highlights the growing trend of leveraging combination therapies that include immunotherapy and other interventions against cancer, such as chemotherapy or anti-angiogenic agents. The use of combination therapies is growing because it often improves the treatment outcomes of patients, especially in individuals who have shown limited response when a single therapy is used.
The authors also reveal that there is a growing use of personalized therapies and cell-based treatments within the immunotherapy segment. These include tumor-infiltrating interventions and CAR-T therapies. As treatment becomes increasingly personalized to address the specific needs of a patient rather than relying on one-size-fits-all approaches, immunotherapies are recording improvements in efficacy and this is helping to increase interest in these therapies.
Additionally, the authors say the market for cancer immunotherapy is poised to grow even faster because manufacturers are constantly seeking better ways to make the therapies. Advances in automation systems, use of setups that leverage closed manufacturing techniques and the use of production units that are localized are helping to deliver affordable and scalable immunotherapies.
The report highlights that the current market for cancer immunotherapy is by and large fragmented and is characterized by established pharmaceutical firms, such as AstraZeneca and Bristol-Myers Squibb, as well as emerging biotechnology companies seeking to establish themselves and claim a share of this rapidly growing market.
With an extensive research pipeline being spearheaded by different firms, such as Calidi Biotherapeutics Inc. (NYSE American: CLDI), cancer immunotherapy is likely to claim an ever-increasing share of the global oncology field given that regulatory frameworks in key markets like the U.S. are supportive of these novel treatments that hold promise in stemming the increasing toll that cancer is taking on not just communities but economies too.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Publishing research in peer-reviewed journals plays a central role in ensuring the credibility and reliability…
LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase…
A team of scientists from Texas Children’s Hospital, University of Pittsburgh and Baylor College of Medicine…
In the life sciences industry, a robust pipeline is widely recognized as a critical driver…
Cardiovascular disease remains the leading cause of death in the United States, representing a significant…
Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance…